title: Enhanced nitric oxide synthesis reverses salt-induced alterations in blood flow and cGMP levels.
abstract: To understand the role of nitric oxide in salt-induced hypertension, we evaluated cardiovascular, hemodynamic and biochemical parameters in Dahl salt-sensitive rats fed low (0.3%) and high (8.0%) sodium diets. Two high salt groups received 1.25 and 2.5 g/L l-arginine in their drinking water. After three weeks of treatment, blood pressure was greater in the high salt groups. l-arginine did not modify salt-induced hypertension. Eicosapentaenoic acid (EPA) caused a smaller depressor response compared to normotensive rats. The increase in blood pressure was associated with decreases in aortic and renal blood flows. In renal artery, the reduction was counteracted by both l-arginine doses; whereas in the aorta, only the higher l-arginine one restored blood flow. The salt-induced reduction in aortic cyclic GMP level was only overcome by the higher l-arginine treatment. These data suggest that at the dose levels tested, nitric oxide reverses the reduction in cGMP and blood flow, but not the blood pressure changes associated with salt-induced hypertension.
authors.affiliation: Department of Pharmacology/Toxicology, Morehouse School of Medicine, Atlanta, GA 30310, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Bayorh
authors.forename: E
authors.initials: E
authors.lastname: Williams
authors.forename: M
authors.initials: M
authors.lastname: Thierry-Palmer
authors.forename: G
authors.initials: G
authors.lastname: Sanford
authors.forename: N
authors.initials: N
authors.lastname: Emmett
authors.forename: S
authors.initials: S
authors.lastname: Harris-Hooker
authors.forename: R R
authors.initials: RR
authors.lastname: Socci
authors.forename: T C
authors.initials: TC
authors.lastname: Chu
mesh_terms: D000818:Animals; D001012:Aorta, Abdominal / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D001120:Arginine / Q000494:pharmacology; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D006152:Cyclic GMP / Q000378:metabolism*; D015118:Eicosapentaenoic Acid / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011863:Radioimmunoassay; D011897:Random Allocation; D051381:Rats; D020303:Rats, Inbred Dahl; D012077:Renal Artery / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D012982:Sodium, Dietary / Q000008:administration & dosage*
chemical_list: D004791:Enzyme Inhibitors; D012982:Sodium, Dietary; D009569:Nitric Oxide; D001120:Arginine; D015118:Eicosapentaenoic Acid; D019001:Nitric Oxide Synthase; D006152:Cyclic GMP; D019331:NG-Nitroarginine Methyl Ester